We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
7.00 | 0.39% | 1,780.50 | 1,778.00 | 1,779.00 | 1,786.50 | 1,771.50 | 1,780.00 | 6,397,670 | 16:35:05 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.86 | 73.22B |
Date | Subject | Author | Discuss |
---|---|---|---|
28/12/2016 11:59 | Don't see much resistance before £16. | woodhawk | |
28/12/2016 11:31 | Creeping higher but on low holiday volumes. | ny boy | |
27/12/2016 17:30 | Monty the Trump bump will run out of steam soon. | ny boy | |
23/12/2016 12:33 | Yes but when you think the FTSE has an average PE of 33 (I'm told) this has a HUGE "margin of safety" as Ben Graham would say. Bought another 1000 yestersday - my biggest holding now | hosede | |
23/12/2016 11:24 | NY BoyPharma's will underperform Trump will kill them on pricing next year. | montyhedge | |
23/12/2016 09:33 | Another woman: GlaxoSmithKline has promoted Deborah Waterhouse to replace ViiV Healthcare's CEO Dominique Limet when he steps down from the HIV-focused firm at the end of March. Limet has served as ViiV's CEO since its 2009 formation as a partnership between GSK and Pfizer, with Shionogi subsequently joining the venture in 2012. He said: “Establishing and then leading ViiV Healthcare for the past seven years has been an incredible honour and extremely fulfilling personally. I have had the pleasure to work with an exceptional team and am proud of how the business has grown to its current position as a leader in HIV therapy. “We have delivered scientific innovation, while listening and better understanding the needs of people living with HIV, allowing us to both do good and do well as a business.” Waterhouse, who is currently senior VP of primary care within GSK's US pharmaceuticals business will take up a CEO designate role at ViiV in January, when she will be replaced by the company's VP of US primary care sales Cheryl MacDiarmid. | tradermichael | |
23/12/2016 09:32 | Should perform well as a defensive play, if the markets correct next year. | ny boy | |
20/12/2016 14:55 | And also helps to take additional market share. | ianood | |
20/12/2016 13:02 | Combos of course cannibalise existing product sales. They do, however, sometimes extend IP protection. | alphorn | |
20/12/2016 12:44 | Head of ViiV states they will submit to regulators next year for the two-drug combo. As both drugs are already approved this will hopefully be a quick process. | essentialinvestor | |
20/12/2016 11:11 | Added some more whilst they are still great value, that's only my take on it though, dyor as usual | ny boy | |
20/12/2016 09:59 | 20th dec Liberum buy tp 1900p reiterates | philanderer | |
20/12/2016 09:58 | The ViiV valuation suddenly became more valuable!. Although so did the put option. Poor Gilead who not so long ago dominated this sector, not any more. | essentialinvestor | |
20/12/2016 09:22 | Yes good phase III results, onwards we go, vols winding down for the holidays now. Q1 should see some healthy buying interest | ny boy | |
20/12/2016 08:48 | Positive news for ViiV on the two-drug regime non inferiority trial. This likely to be the next step in HIV treatment, reducing the number of medications required to maintain viral load suppression. | essentialinvestor | |
19/12/2016 14:46 | It's understandable why there is sometimes a conservative bias, if your livelihood depends on your analysis, how you are viewed by your peer group etc, perhaps easier to follow trend in those circumstances. | essentialinvestor | |
19/12/2016 14:34 | Analysts can sometimes make huge blunders. Some years back I called in an analyst from a major IB who had issued a piece that move the pharma sector. There was a mathematical error in their models that gave a rubbish conclusion. There were red faces but it went under the carpet. | alphorn | |
19/12/2016 14:12 | Often, not always, analysts tend to be reactive and behind the curve. In the case of GSK the Company was until recently lambasted for supposed lack of innovation and new drug development, when even some rudimentary research revealed the opposite to be the case, it just took sometime for consensus to alter. AZN frequently compared very favourably re GSK over the last couple of years, AZN lauded for their innovation and exciting oncology pipeline. Very few people pointed to the major risks with AZN- failure to commercialise this potential would quickly leave the valuation looking very expensive. | essentialinvestor | |
19/12/2016 12:49 | I like the idea of growth, either way suits me, as bought for a long term hold. Keeping 80% in cash for any decent market correction in Q1/2 - 2017 | ny boy | |
19/12/2016 12:28 | Here's another one: Claim that cost of hydrocortisone tablets has risen from 70p to £88 a tablet, costing NHS millions extra, comes after record fine for Pfizer | zho | |
19/12/2016 12:03 | The FT ran another article on pharma pricing yesterday, the price gouging example given was jaw dropping, comparing the UK and US price for a particular medication. No GSK product has been mentioned in any example I have seen. GSK are pricing US new product launches below the level of their medications they are replacing/competing with. The CEO again underscored this last week, also mentioning market response (in take up) was very encouraging as a result. My take on the dividend outlook is very different from consensus, GSK better viewed as a growth company now. There are two potential put options looming in ViiV and the Novartis JV, a dividend rebasing in the context of an investment for growth strategy is what I see- the market should respond very favourably, all just IMV only. | essentialinvestor | |
19/12/2016 10:17 | Agree with the pull back. Keep plenty of cash available for the time being and wait. | philanderer | |
19/12/2016 10:16 | Good point NYB. Still plenty of appetite for defensive high yielders. The only time that would change is when interest rates rise considerably imo. | tim 3 | |
19/12/2016 10:11 | When the markets pull back after this Trump puff rally, gsk may see cash move in as a defensive play. | ny boy | |
19/12/2016 10:03 | My portfolio has done remarkably better in recent years - notably since I stopped taking any notice of brokers' recs. They're just noise. | woodhawk |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions